4 Results for "

liver S9 stability

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "liver S9 stability" in MCE Product Catalog:

Cat. No.: HY-144772
CAS No.: 1580-42-3
Target:  

SARS-CoV

Research Areas:  

Infection

SARS-CoV-2-IN-15 (compound 11) is a potent inhibitor of SARS-CoV-2 with an IC50 of 0.49 μM. SARS-CoV-2-IN-15 is a niclosamide analogue. SARS-CoV-2-IN-15 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally .
loading...
    loading...
Cat. No.: HY-144770
CAS No.: 56961-10-5
Purity:  98.90%
Target:  

SARS-CoV

Research Areas:  

Infection

SARS-CoV-2-IN-13 (compound 5) is a potent inhibitor of SARS-CoV-2 with an IC50 of 0.057 μM. SARS-CoV-2-IN-13 is a niclosamide analogue. SARS-CoV-2-IN-13 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally .
loading...
    loading...
Cat. No.: HY-150681
CAS No.: 2816165-16-7
Target:  

SARS-CoV

Research Areas:  

Infection

SARS-CoV-2 nsp14-IN-2 is a potent SARS-CoV-2 Nsp14 methyltransferase inhibitor with an IC50 value of 0.093 µM. SARS-CoV-2 nsp14-IN-2 shows antiviral activity. SARS-CoV-2 nsp14-IN-2 shows plasma and liver S9 stability. SARS-CoV-2 nsp14-IN-2 has the potential for the research of COVID-19 .
loading...
    loading...
Cat. No.: HY-144771
CAS No.: 22203-98-1
Purity:  99.02%
Target:  

SARS-CoV

Research Areas:  

Infection

SARS-CoV-2-IN-14 (compound 6) is a potent inhibitor of SARS-CoV-2 with an IC50 of 0.39 μM. SARS-CoV-2-IN-14 is a niclosamide analogue. SARS-CoV-2-IN-14 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally .
loading...
    loading...